Lynparza + bevacizumab offers patients with HRD+ aOC the chance to complete treatment after just 2 years1,2
| Lynparza integrated 1L treatment | Monotherapy dosing | Lynparza + bevacizumab dosing | Flexible dosing to support AEs management | Indication
Lynparza integrated 1L maintenance treatment pathway:1,2
*To be eligible for Lynparza + bevacizumab as maintenance, patients are required to have a complete or partial response to 1L platinum-based chemotherapy plus bevacizumab.1
† The licenced dose of bevacizumab is 15 mg/kg Q3W with carboplatin and paclitaxel for up to six cycles, followed by 15 mg/kg Q3W as a single agent, for a total of up to 22 cycles or until
unacceptable toxicity, whichever occurs earlier.1,3,4
Lynparza is available in a tablet formulation for convenient, twice-daily dosing1
*For concomitant administration with CY3PA inhibitors, or use in patients with hepatic or renal impairments, please consult the Lynparza 100 mg and 150 mg tablet Summary of Product Characteristics.
For more information, explore our resource hub or contact an AstraZeneca or MSD representative
Lynparza tablets therapeutic indications1
Lynparza tablets are indicated as monotherapy for:
- The maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
- The maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Lynparza in combination with bevacizumab is indicated for:
- The maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.
Please consult the SmPC for further information before making any prescribing decisions.
1L, first-line; AE, adverse event; aOC, advanced Ovarian Cancer; BRCAm, BRCA1 or BRCA2 mutation; FIGO, Fédération Internationale de Gynécologie et d’Obstétrique; HRD, homologous recombination deficiency; Q3W, every 3 weeks; SmPC, Summary of Product Characteristics.
- Lynparza (olaparib) Summary of Product Characteristics.
- Ray-Coquard I, et al. N Engl J Med. 2023;34:681–692. (plus supplementary appendix).
- Avastin (bevacizumab) Summary of Product Characteristics.
- Ray-Coquard I, et al. N Engl J Med. 2019;381:2416–2428. (plus supplementary appendix).
GB-73570 | Date of Preparation: July 2026
Privacy Policy Terms of Use Contact Us Information for General Public Accessibility
Cookie Preferences
© Merck Sharp & Dohme (UK) Limited 2026. All rights reserved.
© AstraZeneca 2026.
GB-73578 | Date of Preparation: July 2026
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000).
